Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

European regulators to re-examine rimonabant

According to several news sites, including the BBC and PharmaTimes, the European Medicines Agency (EMEA) will review the safety of rimonabant (Acomplia®) next week following the drugs rejection by the FDA, as reported yesterday.

Several of these stories have highlighted the fears about suicide identified by the FDA. This coverage is likely to increase the number of queries from patients already on treatment.

Action: Until the EMEA clarify the European position, it would seem prudent to suspend use of rimonabant in new patients. Patients who are already taking rimonabant and who are concerned about the safety of rimonabant should have treatment stopped and be changed to an alternative therapy if appropriate.

Share 'European regulators to re-examine rimonabant' on Email Share 'European regulators to re-examine rimonabant' on Delicious Share 'European regulators to re-examine rimonabant' on Digg Share 'European regulators to re-examine rimonabant' on Facebook Share 'European regulators to re-examine rimonabant' on Google+ Share 'European regulators to re-examine rimonabant' on reddit Share 'European regulators to re-examine rimonabant' on StumbleUpon Share 'European regulators to re-examine rimonabant' on Twitter

atomic-wealth

One Comments to “European regulators to re-examine rimonabant”

  1. […] in patients taking antidepressants or those with major depression. This announcement follows the EMEA review of the safety of this […]

    Pingback by MHRA Advice On Rimonabant | Prescribing Advice For GPs — July 20, 2007 #
    Reply

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,616 spam comments.

atomic-wealth
fond-illness
summer